このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
急性冠動脈症候群の冠動脈手術後のチカグレロールとアスピリンまたはアスピリン単独
Anders Jeppsson1,2, Stefan James3, Christian H Moller4
1Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
The New England journal of medicine
|September 1, 2025
PubMed で要約を見る
まとめ
冠動脈バイパス移植 (CABG) の後のアスピリン治療にチカグレロルを追加しても,心血管不良は減少しませんでした. アスピリン単独投与と比較して,併用治療は大きな出血のリスクを高めました.
科学分野:
- 心臓病科
- 心血管外科
- 薬理学について
背景:
- 急性冠動脈症候群の冠動脈バイパス移植 (CABG) 後の患者にとって抗血小板治療は極めて重要です.
- この患者集団におけるアスピリンの治療に対するチカグレロの追加効果は不明である.
研究 の 目的:
- アスピリン治療にチカグレロールを加えることで,アスピリン単独投与と比較して,CABG後の不良心血管結果が減少するかどうかを調べる.
主な方法:
- 急性冠動脈症候群でCABGを受けた2201人の患者さんを対象とした,レジストリベースのオープン・ランダム化試験です.
- 患者はチカグレロとアスピリン,またはアスピリン単独を1年間投与した.
- 主なアウトカムは死亡,心筋梗塞,脳卒中,または再血管化でした.
主要な成果:
- ティカグレロとアスピリンのグループ (4. 8%) とアスピリン単独のグループ (4. 6%) の間で主要な結果において有意な差異は認められなかった.
- チカグレロールとアスピリンのグループでは,不良事象の発生率 (9. 1% 対 6. 4%) と大出血の発生率 (4. 9% 対 2. 0%) が高かった.
結論:
- 急性冠動脈症候群のCABGを受けた患者では,アスピリン単独投与と比較して,チカグレロールとアスピリンの併用による主要な心血管疾患の発生率は低下しなかった.
さらに関連する動画
05:41
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.6K
09:21Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
12.1K
関連する概念動画
01:28Acute Coronary Syndrome IV: Interprofessional Care
26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
01:26Acute Coronary Syndrome V: Nursing Management
37
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
37
01:30Acute Coronary Syndrome I: Introduction
71
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
71
01:27Coronary Artery Disease V: Interprofessional Care
30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
01:30Acute Coronary Syndrome III: Diagnostic Studies
23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644